Clearpoint Neuro (CLPT) Investor presentation summary

Market opportunity and unmet needs

• Over 30 million people in the U.S. suffer from severe neurological disorders, with less than 1% treated using minimally invasive neurosurgery.

• Neurological diseases cost nearly $800 billion annually in the U.S., highlighting the need for improved therapies and access.

• 2.1 million U.S. patients have disorders targeted by partners already accepted for FDA expedited review.

Strategic growth and business model

• Four-phase strategy focuses on design, foundation, market penetration, and building a new $10B market with biopharma partners.

• Aims to win 20% of a $1B existing market and generate $200m in annual revenue, with a long-term goal of $500m.

• Over $100m invested in infrastructure, with a global installed base of 175+ centers and 170+ employees.

Product and technology platform

• Unique ecosystem includes neuro navigation, predictive modeling, co-labeled delivery devices, and infusion monitoring software.

• Platform used in 10,000+ procedures, with regulatory approvals in 34 countries.

• Four-pillar growth strategy: biologics & drug delivery, neuro navigation & robotics, laser ablation therapy, and neurocritical care.